FDA Approves Eli Lilly's Zepbound for Weight Loss

United States of America
FDA has approved Eli Lilly's drug tirzepatide, marketed as Zepbound, for weight loss.
The cost for a month's supply of Zepbound is $1,059.87, cheaper than a similar weight-loss drug, Wegovy, priced at $1,349 for a month's supply.
Zepbound works by activating two naturally produced hormones in the body, slowing the emptying of the stomach and suppressing appetite.

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's drug tirzepatide, marketed as Zepbound, for weight loss. The drug was previously approved for the treatment of Type 2 diabetes under the name Mounjaro. The approval allows adults with obesity or overweight with at least one weight-related condition to use the drug for chronic weight management.

Zepbound works by activating two naturally produced hormones in the body, slowing the emptying of the stomach and suppressing appetite. It belongs to a group of drugs that mimic incretins, hormones released by the gut in response to food. The drug is injected once a week in progressively higher doses over up to 20 weeks.

The approval was based on two of Eli Lilly's late-stage trials on tirzepatide, which evaluated its effects on weight loss after 72 weeks. However, access to tirzepatide and other diabetes and obesity treatments remains a challenge due to high costs and insurance coverage issues. The drug can cause side effects such as nausea, vomiting, hair loss, and reflux.

The cost for a month's supply of Zepbound is $1,059.87, which is cheaper than a similar weight-loss drug, Wegovy, made by Novo Nordisk A/S, priced at $1,349 for a month's supply. Zepbound is expected to be available soon after Thanksgiving.

The approval of Zepbound poses a challenge to Novo Nordisk's dominance in the weight loss market. The weight loss market could reach $100 billion by 2035, according to BMO Capital Markets analyst Evan David Seigerman.

Confidence

90%

Doubts
  • There is a contradiction in the percentage of body weight loss reported by different sources.
  • There is a contradiction in the reported cost of the drug by different sources.

Sources

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

FDA Approves Most Potent Weight Loss Drug Yet

TIME Magazine Thursday, 09 November 2023 17:41
  • Unique Points
    • Tirzepatide belongs to a group of drugs that mimic incretins, hormones released by the gut in response to food.
    • The drug can cause side effects such as nausea, vomiting, hair loss, and reflux.
    • It is injected once a week in progressively higher doses over up to 20 weeks.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug

CNBC News Annika Kim Wednesday, 08 November 2023 17:20
  • Unique Points
    • The drug works by activating two naturally produced hormones in the body, slowing the emptying of the stomach and suppressing appetite.
    • The approval was based on two of Eli Lilly's late-stage trials on tirzepatide, which evaluated its effects on weight loss after 72 weeks.
    • However, access to tirzepatide and other diabetes and obesity treatments remains a challenge due to high costs and insurance coverage issues.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

96%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

FDA approves new version of diabetes drug Mounjaro to be sold for weight loss

ABC Philadelphia News Station Wednesday, 08 November 2023 18:21
  • Unique Points
    • The drug, developed by Eli Lilly, has been shown to help dieters lose about a quarter of their body weight in a recent study.
    • However, side effects include gastrointestinal problems.
    • The drug is priced at about $1,000 a month, and many health plans exclude obesity care.
  • Accuracy
    • The drug, developed by Eli Lilly, has been shown to help dieters lose about a quarter of their body weight in a recent study. This contradicts the Time article which states that the drug helps individuals lose about 18% of their body weight.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

FDA Approves Lilly’s Zepbound. A Weight Loss Drug Similar to Ozempic, Wegovy

Bloomberg News Now Madison Muller Thursday, 09 November 2023 17:44
  • Unique Points
    • The cost for a month's supply of Zepbound is $1,059.87, which is cheaper than a similar weight-loss drug, Wegovy, made by Novo Nordisk A/S, priced at $1,349 for a month's supply.
    • Zepbound is expected to be available soon after Thanksgiving.
  • Accuracy
    • The cost for a month's supply of Zepbound is $1,059.87. This contradicts the 6abc article which states that the drug is priced at about $1,000 a month.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug—and it’s nearly $300 cheaper than Wegovy

Fortune Media Inc. Ryan Hogg Thursday, 09 November 2023 00:00
  • Unique Points
    • Pharmaceutical company Eli Lilly has received approval for its diabetes drug Zepbound, which can also aid in weight loss, posing a challenge to Novo Nordisk's dominance in the weight loss market.
    • Zepbound is nearly $300 cheaper than Novo Nordisk's Wegovy.
    • Eli Lilly's other diabetes drug, Mounjaro, also received approval from UK regulators.
    • The weight loss market could reach $100 billion by 2035, according to BMO Capital Markets analyst Evan David Seigerman.
    • Novo Nordisk's CEO, Lars Fruergaard Jørgensen, has indicated that the company could increase its expansion in the US at the expense of Europe if new regulations affecting drug exclusivity are introduced.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication